Peter Lio, MD
Assistant Clinical Professor of
Dermatology & Pediatrics, Northwestern
National Eczema Association
Scientific Advisory Board Member

Skin Microbiome: The key to treating eczema flares

While the role of the Staphylococcus aureus in eczema flares is well understood in the medical community, there have never been options to target it long term without resistance while sparing the commensal bacteria.

Eczema flare severity is correlated with high Staphyloccous colonization and low microbial diversity
(Kong et al, Genome Res. 2012)

Time (Atopic Dermatitis disease progression)

Benefits of Gladskin with Micreobalance™ Endolysin

1

Selectively kills Staphylococcus aureus in-vitro.

2

Preserves the protective commensal bacteria, including S. epidermidis.

3

Endolysin is not expected to induce resistance based on in-vitro study results.

Hear from our Scientific Advisory Board

Play Video
Close

Peter Lio, MD

Board-Certified Dermatologist
Assistant Clinical Professor of Dermatology & Pediatrics, Northwestern University School of Medicine
National Eczema Association Scientific Advisory Board Member

Play Video
Close

Richard Antaya, MD

Board-Certified Dermatologist

Professor of Dermatology, Yale School of Medicine

Director, Pediatric Dermatology, Yale Dermatology Associates

In-vitro study results

99% of S. Aureus, including MRSA, killed while preserving S. epidermidis

*B.L. Herpers et. al Specific lysis of methicillin susceptible

and resistant Staphylococcus aureus by

the endolysin Staphefekt SA.100TM

Zero resistance development after 19 exposition cycles with Micreobalance™

*B.L. Herpers, et. al Specific lysis of methicillin susceptible

and resistant Staphylococcus aureus by

the endolysin Staphefekt SA.100TM

Gladskin has a robust safety profile 

  • Gladskin has been on the market in Europe since 2016 without concerning adverse event reports*
  • Ingredients: Water, Glycerin, Petrolatum, Mineral Oil, Cetearyl Alcohol, Ceteareth-20, Arginine HCl, Sodium Chloride, Tromethamine, Calcium Chloride, Micreobalance™
  • Now Gladskin Eczema Cream is manufactured in a cGMP FDA registered manufacturing facility in the U.S.
  • Safety demonstrated in a placebo controlled trial of patients with Eczema (n=100)
  • Passed 21 Day Cumulative Irritation Test (n=51)
  • Passed Repeated Insult Patch Testing on sensitive skin panel (n=57)
  • Passed phototoxicity panel test (n=22)

Gladskin has been used safely throughout Europe since 2016

German Eczema Patient Study of self-reported outcomes after using Gladskin (European formula) demonstrated 76% of people experienced improvement within a few days.

Speed and degree of response to Gladskin among total

*Study performed on Gladskin Eczema Cream in Europe

Speed and degree of response to Gladskin among responders

*Study performed on Gladskin Eczema Cream in Europe

Instructions for patient and caretaker use

  • Gladskin with Micreobalance™ is available for use without prescription by adults and children 3 months and up.
  • Use Gladskin twice a day, or more as desired, on skin free of other products.
  • Wait at least 5 minutes after applying Gladskin before applying other topical products.
  • There are no known contraindications. Gladskin can be used alongside corticosteroids and other topical and systemic treatments.